Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
68.99
+5.84 (+9.25%)
Streaming Delayed Price
Updated: 1:49 PM EDT, Jun 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
6 Best Healthcare Stocks to Buy Right Now
April 25, 2023
Whether you invest in healthcare stocks for pharmaceuticals, medical devices or health insurance, the opportunities are limitless. Learn more with MarketBeat.
Via
MarketBeat
Topics
Economy
Intellectual Property
Exposures
Economy
Intellectual Property
Product Safety
Gamida Cell Stock Jumps Over 100% on FDA Approval
April 18, 2023
Gamida Cell Ltd. (NASDAQ: GMDA) is an Israeli-based developmental biotechnology company specializing in discovering and advancing cell therapies to fight bloo
Via
MarketBeat
Exposures
Product Safety
Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations
April 16, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Mount Gilead, OH Author Publishes Children's Book
February 02, 2023
This Kids Book Features the Cutest Baby Elephant You Will Ever See!
Via
PR Leap
Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023
April 13, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Balm of Gilead’s Manuka Honey Skin Healing Cream Named “Best for Healing Skin Conditions” by US Weekly Magazine
April 07, 2023
Via
Get News
Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities
March 22, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
March 22, 2023
By Julian Richard, Benzinga
Via
TheNewswire.com
Exposures
Product Safety
Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
March 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
March 20, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
March 08, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Topics
Economy
Exposures
Supply Chain
Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV
February 22, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Kite Completes Acquisition of Tmunity
February 22, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients
February 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies
February 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer
February 17, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Choroidal Neovascularization Market Share Size Trends Overview Analysis 2022-2029
February 16, 2023
Global Choroidal Neovascularization Market to Witness Huge Growth by Key Players: Bausch Health Companies Inc, Bayer AG, Gilead Sciences Inc, F.Hoffmann –La Roche AG,MaaT Pharma Novartis AG, Pfizer...
Via
SBWire
Cholecystitis Treatment Market Demand Trends Outlook Overview Analysis 2022-2029
February 16, 2023
Global Cholecystitis Treatment Market to Witness Huge Growth by Key Players: Boston Scientific, Dornier MedTech GmbH, Fresenius Kabi, AuroMedics Pharmaceuticals, Sanofi, SUNUET Pharmaceuticals, Hetero...
Via
SBWire
Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023
February 14, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Europe Liver Cancer Therapeutics Market to Reach at High CAGR of 8.95% by 2023-2030
February 09, 2023
The Europe liver cancer therapeutics size was valued at US$ 384 million in 2022 and is estimated to reach US$ 627 million by 2030, growing at a CAGR of 8.95% during the forecast period (2023-2030)
Via
SBWire
Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
February 09, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Europe Liver Cancer Therapeutics Market Is at the Cusp of Crossing CAGR of 8.95% N 2023-2030
February 08, 2023
Global Europe Liver Cancer Therapeutics Market to Witness Huge Growth by Key Players: Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly, Bristol-Myers Squibb Company, Gilead...
Via
SBWire
Topics
Death
Exposures
Death
Is Biotech Immunocore About To Make A 25% Price Move?
February 07, 2023
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher.
Via
MarketBeat
Topics
ETFs
U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
February 03, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend
February 02, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results
February 02, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Liposome Drug Delivery Market 2023 in-Depth Analysis, Growth, Size, Future Prospect, Regional Development and Global Outlook 2029
February 02, 2023
Liposome Drug Delivery Market Size, Share and Forecast 2023-2029 Key Players are – Ipsen Pharma, Celsion Corp, Gilead Sciences, Astellas Pharma, Johnson & Johnson, Luye Pharma Group, Novartis AG
Via
SBWire
Exposures
COVID-19
Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer
February 01, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
January 30, 2023
From
Gilead Sciences, Inc. and Arcellx, Inc.
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
January 27, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.